Protectimmun is a Gelsenkirchen, Germany–based biopharmaceutical company focused on research and development of drugs for allergic and chronic inflammatory diseases. The company is developing a pharmaceutical composition, based on research from Ruhr‑University Bochum and Research Centre Borstel, that may offer long‑lasting protection against the development of allergic airway diseases in children. Protectimmun intends to use its recent financing to proceed with pre‑clinical testing and to prepare for clinical studies, according to CEO and co‑founder Dr. Marion Kauth. The company closed a €1.3m first financing round. Investors in the round include High‑Tech Gründerfonds (HTGF), ELS‑Fonds managed by EnjoyVenture, KfW, a private investor and the founding team.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

May 2011